Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 7/2004

01-07-2004 | Brief Report

Vertebral osteomyelitis and epidural abscess in a patient receiving enfuvirtide

Authors: J. Portilla, V. Boix, E. Merino, S. Reus, J. M. Seguí, I. Lopez-Azkarreta

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 7/2004

Login to get access

Excerpt

Reported here is a case of vertebral osteomyelitis and epidural abscess that occurred in a patient receiving enfuvirtide, the first antiretroviral agent to be administered by subcutaneous injection. Since the agent is commonly administered to severely immunocompromised patients, the repeated injections can lead to skin colonization and injury that could be followed by bacteremia and its complications. In addition, certain infections, such as pneumonia, have been related to enfuvirtide use, although a clear pathophysiologic mechanism has not been identified. Patients treated with enfuvirtide need special attention to ensure that a prompt and accurate diagnosis can be made in case complications occur. …
Literature
1.
Kilby JM, Eron JJ (2003) Novel therapies based on mechanisms of HIV-1 cell entry. N Eng J Med 348:2228–2238CrossRef
2.
Cervia JS, Smith MA (2003) Enfuvirtide (T-20): a novel human immunodeficiency virus type-1 fusion inhibitor. Clin Infect Dis 37:1102–1106CrossRefPubMed
3.
Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M, TORO 1 Study Group (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Eng J Med 348:2175–2185CrossRef
4.
Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M, TORO 2 Study Group (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Eng J Med 348:2186–2195CrossRef
5.
Friedman JA, Maher CO, Quast LM, McClelland RL, Ebersold MJ (2002) Spontaneous disc space infections in adults. Surg Neurol 57:81–86CrossRefPubMed
6.
Vergne P, Treves R (1998) Infectious spondylodiscitis. Etiology, diagnosis, progression and treatment. Rev Prat 48:2065–2071PubMed
7.
Tay BK, Deckey J, Hu SS (2002) Spinal infections. Am Acad Orthop Surg 10:188–197
8.
McHenry MC, Easley KA, Locker GA (2002) Vertebral osteomyelitis: long term outcome for 253 patients from 7 Cleveland-area hospitals. Clin Infect Dis 34:1342–1350PubMed
9.
Bergstein JM, Baker EJ IV, Aprahamian C, Schein M, Wittmann DH (1995) Soft tissue abscesses associated with parenteral drug abuse: presentation, microbiology, and treatment. Am Surg 61:1105–1108PubMed
10.
Weisse AB, Heller DR, Schimenti RJ, Montgomery RL, Kapila R (1993) The febrile parenteral drug user: a prospective study in 121 patients. Am J Med 94:274–280PubMed
11.
Chantelau E, Lange G, Sonneberg G (1987) Acute cutaneous complications and catheter needle colonization during insulin pump treatment. Diabetes Care 10:478–482PubMed
Metadata
Title
Vertebral osteomyelitis and epidural abscess in a patient receiving enfuvirtide
Authors
J. Portilla
V. Boix
E. Merino
S. Reus
J. M. Seguí
I. Lopez-Azkarreta
Publication date
01-07-2004
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 7/2004
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-004-1153-1

Other articles of this Issue 7/2004

European Journal of Clinical Microbiology & Infectious Diseases 7/2004 Go to the issue

Brief Report

Group B Streptococcus necrotizing fasciitis: an emerging disease?

Article

Incidence and etiological agents of bacterial meningitis among children <5 years of age in two districts of Romania

Article

Epidemiology of meningococcal disease in Switzerland, 1999–2002

Article

Pneumocystis jiroveci isolates with dihydropteroate synthase mutations in patients with chronic bronchitis

Concise Article

Cytomegalovirus encephalitis in an immunocompetent pregnant woman

Concise Article

Mycobacterium malmoense lymphadenitis in Spain: first two cases in immunocompetent patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits